Drug intelligence / Profile preview

iparomlimab + tuvonralimab + cisplatin + nab-paclitaxel

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This investigational combination therapy, evaluated in the NICE-CC trial (NCT07055399), consists of the bifunctional antibody QL1706 (a co-formulation of iparomlimab and tuvonralimab) combined with cisplatin and nab-paclitaxel chemotherapy. QL1706 is a MabPair biologic that simultaneously targets the PD-1 and CTLA-4 immune checkpoint pathways to restore and enhance anti-tumor T-cell activity. Iparomlimab is an anti-PD-1 IgG4 antibody, while tuvonralimab is an anti-CTLA-4 IgG1 antibody. The chemotherapy components, cisplatin (a platinum-based DNA alkylator) and nab-paclitaxel (an albumin-bound microtubule inhibitor), provide direct cytotoxic effects. This regimen is being studied as a neoadjuvant treatment for patients with locally advanced cervical cancer (LACC) to improve surgical outcomes and pathological complete response rates.

Brand names: Anbeijia
Other names: NICE-CC regimenQL1706 plus cisplatin and nab-paclitaxelQL-1706 plus cisplatin and nab-paclitaxelQL 1706 plus cisplatin and nab-paclitaxel

Targets

TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA

Beyond the preview

Go deeper on iparomlimab + tuvonralimab + cisplatin + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iparomlimab + tuvonralimab + cisplatin + nab-paclitaxel.

Explore the full profile